Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo

This article was originally published in The Tan Sheet

Executive Summary

Two ANDA approvals expected "very shortly," with six to eight additional approvals likely in 12-15 months following private labeler's resolution of quality control problems cited in August warning letter, President & CEO David Gibbons says at UBS Warburg Global Specialty Pharmaceuticals Conference May 23. "We have recently been notified by the FDA that we have satisfactorily addressed the issues...and we are now able to get our ANDAs approved," Gibbons says. Perrigo has nine ANDAs pending with the agency; firm is eyeing near-term launches of private label Pepcid AC, Advil Cold & Sinus, Rogaine Extra Strength, Excedrin Migraine and NasalCrom
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS092598

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel